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Pharmacy Help Desk Service
Farhat Zaheer-Specialist, Ambulatory Care Pharmacy

“A Customer centric approach to enhance patients’ safety and compliance
through improved patient-pharmacist coordination.”
Ambulatory care pharmacy practice is the
provision of integrated, accessible health
care services by pharmacists who are
accountable for addressing medication needs
and developing sustained relationship with
patients. This is accomplished through direct
patient-pharmacist interaction, medication
management, counseling and specialized
services for ambulatory patients .The
ambulatory care pharmacists are involved in
direct care of a diverse patient population.
Researches have shown an increased risk of errors in ambulatory care
including diagnostic and medication errors as the likelihood of an error
is linked to a patient’s understanding of the indication, dosage schedule,
proper administration, and potential adverse effects. Inability of patient to
understand their medication schedule, side effects and possible interaction
with other prescribed drug may compromise safety in short term and
clinical outcomes in long term. Various factors like space constraint,
insufficient counters and high volumes in ambulatory care pharmacies
account for insufficient pharmacist-patient interactions, accessibility and
timely responses for medication related queries.
In order to enhance patient-pharmacist interaction and to facilitate safe
use of medications and patient’s compliance, pharmacy help desk was
established at IBN-ZUHR front desk. It serves as an accessible and
affordable way to address customer’s queries related to medication and
their usage. It provides assistance to patients for:
l
l
l

Drug availability, price
Dosage, regime
Directions for administration, precautions and drug interactions.

Patients are being facilitated through online email service, dedicated
telephonic assistance, and qualified pharmacist services at help desk counter.
Help desk services operates between 10 am till 2 pm, five days a week and
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24/7 email service. Increased pharmacist-patient coordination not only enhances community’s awareness regarding
medication usage but also serves as effective tool to minimize abrupt discontinuation of therapy and risk of selfmedication.
Pharmacy help desk has received an over-whelming response from customers since initiation of its services
in June 2016 with over all 800 plus drug responses by pharmacist in the form of emails, telephonic calls and
medication counseling services. More than 70 appreciations were received within one month. The services and
coverage will be extended in phase-2 with more focus on specialized counseling services for specific disease
and its medications like oncology and anti-coagulation counseling services. It will also initiate some value
added service like refill reminders, advance booking for compounded medications to facilitate patients.

New Guidelines for the Management of Aspergillosis
Kashif Hussain-Specialist, Infectious Disease

Early diagnosis and treatment of the major forms of aspergillosis are the focus of a new practice guideline
from the Infectious Diseases Society of America (IDSA). The evidence-based recommendations highlight data
from clinical studies that evaluated new and current therapies for the management of Aspergillus infection, as
well as data on the use of non-culture-based biomarkers for diagnosing infection. In particular, the guidelines
focus on the management of the major forms of aspergillosis (allergic, chronic, and invasive), with special
emphasis on invasive aspergillosis because it remains a significant cause of morbidity and mortality in highrisk,immune-compromised patients.
It is emphasized that improved use of diagnostic tools has increased clinicians’ ability to make an early
diagnosis of aspergillosis. Until molecular diagnostic techniques become more widely used in clinical
laboratories, the guidelines recommend submission of tissue and fluid specimens for histopathologic,
cytologic, and culture examination to diagnose invasive aspergillosis (IA). However, molecular techniques,
such as DNA sequencing, should be used to identify Aspergillus species in cases that involve either isolates
with atypical growth or concern for resistance.
If invasive pulmonary aspergillosis (IPA) is suspected in a patient, the guidelines recommend performing
computed tomography scanning of the chest, regardless of chest radiography findings. Bronchoscopy with
bronchoalveolar lavage is also recommended in these patients, unless significant comorbidities (such as
bleeding or severe hypoxemia) preclude it. Detection of galactomannan (a component of the Aspergillus
cell wall) in serum or bronchoalveolar lavage fluid is recommended as an accurate marker for the diagnosis
of invasive aspergillosis in adults and children, when used in certain patient subpopulations, such as
hematopoietic stem cell transplant recipients or patients with hematologic malignancies. The guidelines
also discuss emerging diagnostic tools with the ability to further improve the early diagnosis of Aspergillus
infection. For instance, Aspergillus polymerase chain reaction (PCR) testing has been shown to be more
sensitive than culture in detecting the fungus in blood and respiratory fluids. Nevertheless, a promising
diagnostic tool, these assays have not been standardized and validated for routine clinical use, and the role of
PCR testing in patient management remains unclear.
The availability of antifungal agents that are more active, better tolerated, and/or developed in extended-release
formulations has also substantially improved therapy for patients at risk for serious Aspergillus infections.
If IPA is suspected, antifungal therapy should be initiated while diagnostic evaluation is ongoing. Voriconazole
is recommended for primary treatment of IPA, although combination therapy with voriconazole and
echinocandin may be warranted for some high-risk patients. Antifungal therapy for IPA should continue for at
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least 6 to 12 weeks. Antifungal prophylaxis should also be instituted for patients with prolonged neutropenia
who are at high risk for IA. Prophylactic regimens with posaconazole, voriconazole, and/or micafungin are
considered to be most effective. The guidelines do not recommend routine testing for antifungal susceptibility.
Instead, it should be reserved for cases in which infection with an azole-resistant isolate is suspected, or in
which a patient is unresponsive to antifungal agents.
The guideline, which has also been endorsed by the Pediatric Infectious Diseases Society, recommends using
the same antifungal agents for treatment of aspergillosis in children as are used in adults. However, dosing of
many of these agents may be different for children. The authors also note that although voriconazole is only
approved by the US Food and Drug Administration for children aged 12 years and older, it is the cornerstone
of aspergillosis treatment in children of all ages. Yet, despite recent advances, the authors acknowledge that
development of new antifungal agents is still needed for effective management of aspergillosis, because “even
with optimal antifungal therapy the mortality rate remains high.”

Flu Vaccine
Ale Zehra , Clinical Pharmacist
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Overview of New CHEST Antithrombotic Guideline for Treatment of
VTE (10th Edition)
Nida Najmi, Clinical Pharmacist, Ambulatory Care Pharmacy

American College of Chest Physicians (ACCP) issued new Antithrombotic Guidelines for the treatment of
Venous Thromboembolism in January, 2016. This guideline provides most recent treatment options for VTE
patients with updated recommendations on 12 topics that were in the 9th edition of these guidelines, and address
3 new topics. Following are the 11 key points about this updated guideline:
l

l

l

l

l

l

l

l

l

l

l

For VTE without an associated cancer diagnosis, all direct oral anticoagulants (dabigatran, rivaroxaban,
apixaban, or edoxaban) are recommended over vitamin K antagonist (VKA) therapy (all Grade 2B) and
VKA therapy is recommended over low molecular weight heparin (LMWH; Grade 2C).
For VTE associated with cancer, LMWH is recommended over VKA (Grade 2B) or any direct oral
anticoagulants (all Grade 2C).
Anticoagulants should stop after 3 months of therapy in patients with an acute, proximal deep venous
thrombosis (DVT) provoked by surgery rather than shorter or longer treatment courses (Grade 1B).
Anticoagulants should also be stopped after 3 months in patients with a proximal DVT or pulmonary
embolism (PE) provoked by a nonsurgical transient risk factor over shorter or longer courses (Grade 1B for
high bleeding risk patients, Grade 2B for low or moderate bleeding risk patients).
Anticoagulation should be given for 3 months in patients with a first unprovoked VTE and a high risk of
bleeding (Grade 1B), but should be extended without a scheduled stop date in patients with a low or moderate
risk of bleeding (Grade 2B).
For patients with acute VTE who are treated with anticoagulation, the guideline recommends against the use
of an inferior vena cava filter (Grade 1B).
For patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy, the guideline
suggests the use of aspirin over no aspirin to prevent recurrent VTE if there are no contraindications to
aspirin therapy (Grade 2B).
For patients with acute DVT, the guideline recommends against the use of compression stockings routinely
to prevent the post-thrombotic syndrome (Grade 2B).
For patient with subsegmental PE and no DVT, the guideline suggests clinical surveillance over anticoagulation
when the risk of VTE recurrence is low (Grade 2C). The guideline recommends the use of anticoagulation
over surveillance when the risk of VTE recurrence is high (Grade 2C).
For patients with an acute PE and hypotension (massive PE), the guideline recommends the use of
thrombolytic therapy (Grade 2B), preferring systemic therapy over catheter-directed thrombolytic therapy
(Grade 2C).
For patients with recurrent VTE while treated with a non-LMWH anticoagulant, the guideline recommends
changing to LMWH therapy (Grade 2C). If patients suffer a recurrent VTE while on LMWH treatment, the
guideline recommends increasing the LMWH dose (Grade 2C).
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From Pain Killer to Empathy Killer
Nida Saleem, Trainee Pharmacist

A new study conducted by researchers at Ohio State University (Dominik Mischkowski, Jennifer Crocker, Baldwin
M. Way, 2016) found that acetaminophen or paracetamol dulls a person to the trials and tribulations of other.
This research also suggests that one become careless of other’s feelings. In two double-blind placebo-controlled
experiments, participants perceived pain, personal distress and empathetic concerns in response to physical or
social pain scenarios. As if hypnotized, acetaminophen reduced empathy in response to other’s pain. Because
empathy regulates the pro-social and antisocial behavior, this drug-induced reduction in compassion has raised
concern about broader social effects of acetaminophen, which is widely taken by patients on daily basis.

Insulin needle Length : Does it really matter?
Khuban Arshad , Pharmacist, Ambulatory Care Pharmacy

Patients usually have apprehensions about the 4mm needles available in the AKUH pharmacies. Insulin is
meant to be injected into the subcutaneous tissues and its thickness varies according to different sites ie arm,
thigh, abdomen,etc. On average, thickness of human skin along with subcutaneous tissue is more than 2.8mm.
Therefore, 4mm syringes can be safely used for insulin administration. Pharmacist can play a significant role in
helping patients overcome their fear of injecting too deep. Pharmacists should
also counsel patients about selecting injection sites according to body weight/
BMI as mentioned in Figure 01. For example, choosing buttocks as the site of
administration for abdominally obese patients can go a long way promoting
insulin acceptance and adherence.
Figure 01

Immunization against Pneumococcal
Amna Mujeeb , Pharmacist, Inpatient Pharmacy

Two types of pneumococcal vaccinations for adults are available at AKUH pharmacy ie PCV13 & PPSV
23. The former provides coverage against 13 strains and latter against 23 strains causing pneumonia. The
important consideration in pneumococcal vaccination is the order & timing interval. Since, these two types of
immunizations stimulate the immune system in different ways; therefore, the timing & order of administration
are very important. Immune response is faster if PCV 13 is given first. Interval between PPSV23 & PCV 13
depends upon age Group, medical condition, last administered vaccine, high risk group.
Interval Recommendation:
PSV23

1 year Interval

PCV 13

PPSV23

5 year Interval

PPPSV23

PCV 13

Age Medical Condition

PPSV23
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Recommended Interval:
Medical Condition

Age Group

Vaccination Protocol

Immuno-compromised
Asplenic

PCV13 8 WEEKS INTERVAL  1st dose PPSV23
5 YEARS INTERVAL  2nd dose PPSV23

High-Risk immunocompetent
Cochlear implants
HIV but receive one dose
PPSV23 one year ago

PCV13 8 WEEKS INTERVAL  1st dose
PPSV232ND DOSE PPSV23 at age 65
give PCV13 stat2nd dose PPSV23 after 5 years
interval of 1st dose PPSV23 3rd dose PPSV23 at age
65 year

19yrs – 64yrs

Asthma

PPSV23  PCV13 at age 65  1 year interval  2nd
dose PPSV23

Asthma + long term
systemic corticosteroids

PCV13 stat 8 WEEKS INTERVAL  1st dose
PPSV23 2ND DOSE PPSV23 at age 65

Geriatric with no vaccine history

65yrs & older

PCV13 1 year INTERVAL  PPSV23

Geriatric with PPSV23

65yrs & older

Give PCV13 considering 1 year interval from last
received PPSV23

Targeting the Low Anticoagulation Therapy in Valve Replacement
Fahmeen Kinza, Trainee Pharmacist

Anticoagulation regimens vary according to practice of surgeon, nature of the valve (mechanical or biological),
position of valve and prevention of other risk factors including stroke etc. INR recommendations of the The
American College of Chest Physicians (ACCP) 2016 in various conditions ie mechanical valve in the aortic
position, mitral position (MVR), Atrial Fibrillation and Prosthetic Valve Replacement are given in Table 01.
Furthermore, several studies have shown the effectiveness of low target INR, when anticoagulant is used in
combination with low dose aspirin, to significantly lower the risk of bleeding and thromboembolism. Tables 01
summarizes the ACCP recommendations and mean range of low INR therapy of several studies.
Table 01:

Condition

INR – ACCP Guideline

Low INR Levels ( Studies Based)

Mitral Valve Replacement (MVR)

2.5-3.5

1.8-3.0

Atrial Valve Replacement (AVR)

2.0-3.5

1.3-2.5

Atrial Fibrillation

2.0-3.0

1.5-2.1

Prosthetic Valve Replacement

3.0-4.5

2.0-3.0

*** In April 2015 FDA approved the On-X aortic heart valve with INR 1.5–2.0 following 3 months of standard anticoagulation therapy based on
the successful completion of the AVR high risk arm of the PROACT study
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Time Saving Facilities for Employees at AKUH
Durr-e-Shahwar Siddiqui , Pharmacist, Ambulatory Care Pharmacy

Aga Khan University Hospital is well-known worldwide for providing excellent healthcare services to its customers. We highly value our external as well as internal customers. For the accomplishment of our objective in
rendering a better framework of pharmacy services at AKUH, we remain indulged in expanding the quality of
pharmaceutical care. Following are the time-saving pharmacy facilities for AKUH staff,
“PHAMED” For Doctors
A request e-mail can be sent by doctor at phamed@aku.edu for any required formulary
medicine along-with the needed quantity, name & employee number. The requested
order is then processed by the pharmacist & the employee is informed by a confirmatory
e-mail after which the order can be collected by Nazar Ali Walji Pharmacy (Ext: 5702).
This facility can be used for both prescription and over the counter medicines.
E-Pharmacy for All AKUH Employees
AKUH employee can place the order for available over-the-counter (OTC) medicines
at website ie http://intranet/epharmacy . The processed order can by collected from
Community Health Centre Pharmacy (Ext: 1512) after an approval e-mail is sent to
employee stating that is/her order has completed.
The above mentioned pharmacy facilities can surely save the time of our respected internal customers of
AKUH which they spend in the queues of pharmacy. The saved time can be utilized for benefiting the patients.
Hopefully the satisfaction levels of both the internal & external customers will be raised by such advantageous
pharmaceutical services of AKUH.

FDA Warnings 2016
Abdul Rauf- Pharmacist, Ambulatory Care Pharmacy

Drug of Concern

Warning

Recommendations

Fluoroquinolones,
Antibiotics

Systemic use is associated with the serious side
effects including tendon, joint and muscle pain,”
tingling or pricking sensation, confusion, and hallucinations.

Restricting its use for certain uncomplicated infections where other treatment
options are not available.

Aripiprazole,
Antipsychotic

Uncontrollable urges to gamble, binge eat, shop,
and have sex have been reported.

Aware patient about the risk of these
uncontrollable urges and specifically
ask about any new or increasing urges

Olanzapine,
Antipsychotic

Drug Reaction with Eosinophilia and Systemic
Symptoms (DRESS), a rare but serious skin
reaction, has been reported with its use.

Explain signs and symptoms. Advise
patients to seek immediate
medical care if DRESS is suspected.

Fluconazole,
Antifungal
Ketoconazole,
Antifungal

Advise precaution
A Danish Study showed increased risk of
miscarriage with use of oral fluconazole.
High risk of serious liver damage and adrenal gland Suggest other agents to treat skin and
problems with oral fluconazole
nail fungal infections
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Drug of Concern
Loperamide,
Antidiarrheal
Opioids
Analgesics

Warning

Recommendations

Serious heart problems that can lead to death.

Follow the label’s dosing
recommendations

May cause adrenal insufficiency, serotonin syndrome
(if used in combination with antidepressant or
migraine medications) and long term use may result
in decreased sex hormone levels and symptoms (low
interest in sex, impotence, or infertility)

Discontinue treatment in case of
serotonin syndrome and perform
diagnostic testing if adrenal
insufficiency is suspected.

Ask Away!
You may get an experts opinion by consulting with one of our specialist. Send in your questions at
drug.information@aku.edu

Take Action and Report an

Adverse Drug Reaction!
WHO defines adverse drugs reaction as:
“A response to a drug which is noxious, unintended, and which occurs at doses
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for
the modifications of physiological function.”

Why Report?
P

For continuous monitoring for ADR trends at AKUH

P

To develop strategies for prevention of any complications

P

To assess the quality of pharmaceutical care

P

To evaluate safety of drug therapies, especially recently approved drugs

P

To reduce the hospitalization of patient and minimize liability of our hospital

How to Report?
1. Call ADR Hotline- Ext 1477 ( 34861477)
2. Report Online : http://intranet/pharmacy/adrrf.htm

3. Fill out “ Yellow Cards”

Provide us your Valuable Feedback!

LINK: https://docs.google.com/forms/d/1IAduMbPm_X9yP9lN-OvpdYEEQLWFycho4U6uQWXet3c/edit#
the feedback form can be emailed to you as well. Just drops us an email with the Subject Newsletter Feedback
Email us at: drug.information@aku.edu

The Aga Khan University Hospital, Karachi

